Q2 EPS Estimate for Nektar Therapeutics Reduced by Analyst

Nektar Therapeutics (NASDAQ:NKTR) – Equities research analysts at HC Wainwright lowered their Q2 2025 earnings per share (EPS) estimates for shares of Nektar Therapeutics in a research note issued to investors on Monday, May 12th. HC Wainwright analyst A. He now anticipates that the biopharmaceutical company will post earnings of ($0.18) per share for the quarter, down from their previous forecast of ($0.15). HC Wainwright has a “Buy” rating and a $6.50 price objective on the stock. The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($0.72) per share. HC Wainwright also issued estimates for Nektar Therapeutics’ Q3 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.77) EPS and FY2026 earnings at ($0.84) EPS.

Several other equities analysts have also recently issued reports on NKTR. William Blair reiterated a “market perform” rating on shares of Nektar Therapeutics in a research report on Monday. StockNews.com cut Nektar Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday. Oppenheimer upgraded Nektar Therapeutics from a “market perform” rating to an “outperform” rating and set a $6.00 price target on the stock in a research report on Friday, March 14th. Finally, Jefferies Financial Group upgraded Nektar Therapeutics from a “hold” rating to a “buy” rating and lifted their price target for the company from $1.00 to $2.00 in a research report on Friday, April 11th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $4.50.

Nektar Therapeutics Stock Performance

Shares of NKTR stock opened at $0.68 on Wednesday. Nektar Therapeutics has a 1 year low of $0.43 and a 1 year high of $1.83. The stock has a market cap of $126.55 million, a PE ratio of -0.81 and a beta of 0.62. The business’s fifty day moving average is $0.70 and its 200-day moving average is $0.89.

Nektar Therapeutics (NASDAQ:NKTR) last announced its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.04). The business had revenue of $10.46 million for the quarter, compared to the consensus estimate of $15.61 million. Nektar Therapeutics had a negative net margin of 180.70% and a negative return on equity of 173.28%. During the same period in the previous year, the firm earned ($0.18) EPS.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Nantahala Capital Management LLC lifted its stake in shares of Nektar Therapeutics by 90.0% in the 4th quarter. Nantahala Capital Management LLC now owns 7,810,000 shares of the biopharmaceutical company’s stock valued at $7,263,000 after purchasing an additional 3,700,000 shares during the period. Woodline Partners LP increased its position in shares of Nektar Therapeutics by 187.3% in the 4th quarter. Woodline Partners LP now owns 4,974,512 shares of the biopharmaceutical company’s stock valued at $4,626,000 after buying an additional 3,242,841 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Nektar Therapeutics by 17.5% in the 4th quarter. Renaissance Technologies LLC now owns 3,910,786 shares of the biopharmaceutical company’s stock valued at $3,637,000 after buying an additional 583,153 shares in the last quarter. Altium Capital Management LLC increased its position in shares of Nektar Therapeutics by 26,172.0% in the 4th quarter. Altium Capital Management LLC now owns 3,000,000 shares of the biopharmaceutical company’s stock valued at $2,790,000 after buying an additional 2,988,581 shares in the last quarter. Finally, 22NW LP bought a new stake in shares of Nektar Therapeutics in the 4th quarter valued at $2,038,000. Institutional investors and hedge funds own 75.88% of the company’s stock.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.